These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21521310)

  • 1. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
    Chung HY; Chin SO; Kang MI; Koh JM; Moon SH; Yoon BK; Yoon HK; Chung YS; Park HM
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):699-704. PubMed ID: 21521310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
    Chung HY; Koo J; Kwon SK; Kang MI; Moon SH; Park JY; Shin CS; Yoon BK; Yoon HK; Chang JS; Chung YS; Park HM
    Clin Interv Aging; 2013; 8():597-603. PubMed ID: 23761968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
    Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
    J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Between-meal risedronate does not alter bone turnover in nursing home residents.
    Agrawal S; Krueger DC; Engelke JA; Nest LJ; Krause PF; Drinka PJ; Binkley NC
    J Am Geriatr Soc; 2006 May; 54(5):790-5. PubMed ID: 16696745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
    Li Y; Zhang Z; Deng X; Chen L
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):527-9. PubMed ID: 16463664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecalciferol Supplementation Promotes Bone Turnover in Chinese Adults with Vitamin D Deficiency.
    Yao P; Sun L; Xiong Q; Xu X; Li H; Lin X
    J Nutr; 2018 May; 148(5):746-751. PubMed ID: 29897564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
    Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA; Vinicola V
    Minerva Endocrinol; 2019 Dec; 44(4):344-350. PubMed ID: 31971357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
    Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.
    Chandra P; Binongo JN; Ziegler TR; Schlanger LE; Wang W; Someren JT; Tangpricha V
    Endocr Pract; 2008; 14(1):10-7. PubMed ID: 18238736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.